MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MoonLake ImmunotherapeuticsNASDAQ: MLTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 71.27M shares rose 12.7% year over year, ahead of the +4.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +30.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.7% holds above the trailing-twelve-month pace of +4.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
71.27M+10.6% QoQ
Last fiscal yearDec 2025
64.46M+2.5% YoY
LTMMar 2026
65.6M+4.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.7%——
1 year+2.5%——
3-year CAGR+30.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
64.46M USD
Year-over-year change
+2.5%
4-year CAGR
+14.9%

Weighted Avg Shares (Diluted) vs competitors

How MLTX compares with its peers on the latest reported figures

  • MLTX's LTM Mar 2026 weighted avg shares (diluted) of 65.6M shares is the 5th highest of the 11 companies compared; the peer median is 62.96M shares.
  • Its year-over-year change of +4.1% is the 8th highest of 11, against a peer median of +33.0%.
  • Over three fiscal years its annual growth of +30.0% compares with a peer median of +39.7%.
MLTX Competitors Peer median
Weighted Avg Shares (Diluted) for MLTX and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.6%+384.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
ORKAOruka Therapeutics, Inc.LTM Sep 202661.01M +68.6%+46.8%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
DNTHDianthus Therapeutics, Inc.LTM Jun 202644.91M +27.5%+116.1%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
Peer median (excluding MLTX) 62.96M+33.0%+39.7%

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.97K0002.62M
Gross Profit(4.97K)000(2.62M)
Gross Margin—————
Research & Development35.52M42.05M31.8M112.77M202.86M
Selling, General & Admin18.05M23.01M22.32M30.32M41.97M
Operating Expenses53.57M65.06M54.12M143.09M242.22M
Depreciation & Amortization4.97K164.78K370.32K1.38M2.62M
EBITDA(53.63M)(64.3M)(43.61M)(119.58M)(219.85M)
EBITDA Margin—————
Operating Income(53.58M)(65.06M)(54.12M)(143.09M)(244.83M)
Operating Margin—————
Interest Income00000
Interest Expense00007.25M
Other Income / Expenses(61.85K)591.73K10.14M22.13M15.12M
Income Before Tax(53.64M)(64.47M)(43.98M)(120.96M)(229.71M)
Pre-Tax Margin—————
Income Tax Expense4.76K36.37K94.39K282.2K611K
Net Income(53.64M)(49.97M)(36.01M)(118.94M)(227.32M)
Net Margin—————
EPS (Basic)(1.45)(2.20)(0.73)(1.89)(3.53)
EPS (Diluted)(1.45)(2.20)(0.73)(1.89)(3.53)
Weighted Avg Shares36.93M29.36M49.12M62.87M64.46M
Weighted Avg Shares (Diluted)36.93M29.36M49.12M62.87M64.46M

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.